Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis

作     者：Radan Bruha Marie Jachymova Jaromir Petrtyl Karel Dvorak Martin Lenicek Petr Urbanek Tomislav Svestka Libor Vitek 

作者机构：4~(th) Department of Internal Medicine 1~(st) Faculty of Medicine and General University Hospital Charles University in Prague Institute of Clinical Biochemistry and Laboratory Diagnostics 1~(st) Faculty of Medicine Charles University in Prague Department of Internal Medicine Central Military Hospital and 1~(st) Faculty of Medicine Charles University in Prague 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2016年第22卷第12期

页      面：3441-3450页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by The Internal Grant Agency of the Czech Ministry of Health(http://iga.mzcr.cz/public Web/),No.NT 12290/4 the Charles University in Prague(http://www.cuni.cz/UKEN-1.html),No.SVV 260156/2015 the Czech Ministry of Health(http://mzcr.cz),No.MZCR-RVO VFN64165 

主　　题：Cirrhosis Complications of cirrhosis Hepatic venous pressure gradient Osteopontin Portal hypertension Prognosis Survival prediction 

摘      要：AIM: To investigate the relationship between osteopontin plasma concentrations and the severity of portal hypertension and to assess osteopontin prognostic ***: A cohort of 154 patients with confirmed liver cirrhosis (112 ethylic, 108 men, age 34-72 years) were enrolled in the study. Hepatic venous pressure gradient (HVPG) measurement and laboratory and ultrasound examinations were carried out for all patients. HVPG was measured using a standard catheterization method with the balloon wedge technique. Osteopontin was measured using the enzyme-linked immunosorbent assay (ELISA) method in plasma. Patients were followed up with a specific focus on mortality. The control group consisted of 137 healthy age- and sex- matched ***: The mean value of HVPG was 16.18 ± 5.6 mmHg. Compared to controls, the plasma levels of osteopontin in cirrhotic patients were significantly higher (P 10 mmHg and 65% for those with HVPG ≤ 10 mmHg (P = 0.0086, odds ratio (OR), 2.92, 95% confidence interval (CI): 1.09-7.76). Osteopontin showed a similar prognostic value to HVPG. Patients with osteopontin values above 80 ng/mL had significantly lower cumulative survival compared to those with osteopontin ≤ 80 ng/mL (37% vs 56%, P = 0.00035; OR = 2.23, 95%CI: 1.06-4.68).CONCLUSION: Osteopontin is a non-invasive parameter of portal hypertension that distinguishes patients with clinically significant portal hypertension. It is a strong prognostic factor for survival.